RARE DISEASE
Gaucher disease type 1
Gaucher disease type 1
Gaucher disease type 1
Synonyms: Non-cerebral juvenile Gaucher disease
Synonyms: Non-cerebral juvenile Gaucher disease
Synonyms: Non-cerebral juvenile Gaucher disease
Drug discovery
3
drugs
With orphan designations
Overview
Gaucher disease type 1 (GD1) is an autosomal recessive lysosomal storage disorder caused by GBA gene mutations, resulting in deficient glucocerebrosidase activity and accumulation of glucocerebroside. It manifests with hepatosplenomegaly, cytopenias, bone complications (osteopenia, fractures), and fatigue, without primary neurological involvement [1][2][7]. Treatment focuses on enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) to mitigate visceral and hematological symptoms, though skeletal complications often persist [3][6][13].
Burden
Chronic complications: Bone pain, avascular necrosis, osteoporosis, and irreversible organ damage without early treatment [6][7][15]
Economic impact: Annual ERT costs exceed $200,000–$400,000 per patient [5][17]
Quality of life: Persistent fatigue, mobility limitations, and delayed growth/puberty in pediatric patients [9][15][19]
Therapies
ERT: Intravenous infusions (e.g., imiglucerase, velaglucerase) every 2 weeks to reduce substrate accumulation [1][6][17]
SRT: Oral agents (e.g., eliglustat, miglustat) to limit glucocerebroside synthesis [3][8][13]
Adjunctive care: Bisphosphonates for bone disease; transfusions for severe cytopenias [6][13]
Categories: rare bone diseases, rare cardiac diseases, rare genetic diseases, rare inborn errors of metabolism, rare neurological diseases, rare ophthalmic disorders, rare respiratory diseases, rare systemic and rheumatological diseases, rare transplant-related disorders
Research Papers
1,470 drug discovery papers about Gaucher disease type 1, with 6 first-in-class and 9 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
1,470 drug discovery papers about Gaucher disease type 1, with 6 first-in-class and 9 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-06 | Plain language summary: A real-world analysis of long-term treatment with eliglustat in people with Gaucher disease type 1
Plain Language SummaryWhat did this study look at?Gaucher disease type 1 (GD1) is a rare genetic condition. It results from a problem with an enzyme (a protein that speeds up chemical reactions in the body) called acid beta-glucosidase. This enzyme normally helps break down excess fats in the body called sphingolipids. As a result, fats build up inside certain cells (called lysosomes) especially in organs like the liver and spleen, in bones, and in the blood. Symptoms of GD1 include enlarged liver and spleen, low haemoglobin (a protein in red blood cells that carries oxygen), low platelets (specialised blood cells that help blood clot), poor bone health, and fatigue.People with GD1 experience a wide range of symptoms, severity, and disease worsening. This makes it difficult to understand how well treatments work in everyday clinical care as clinical trials often include only a limited group of patients.The study looks at how effective (how well something works) eliglustat is in routine clinical practice across a broader spectrum of adults with GD1 than those who participated in clinical trials.Researchers used data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. This is a global database that follows people with Gaucher disease over many years. Since the Registry includes people with diverse backgrounds, disease severities, and treatment histories, it provides valuable insight into how treatments perform outside of controlled trials.Using this real-world data, the study examines long-term outcomes in adults with GD1 who started eliglustat. This includes both people who had never received treatment before and those who switched from enzyme replacement therapy (ERT).What were the results of the study?Researchers looked at adults with GD1 who started eliglustat treatment and followed them for up to 10 years.For people who had not received any treatment for Gaucher disease (GD) prior to receiving eliglustat, blood counts and organ size (spleen and liver) improved and bone health (measured by bone mineral density) remained stable over 4 years. For people who switched to eliglustat after receiving ERT, blood counts, organ size (spleen and liver), and bone health remained stable after switching to eliglustat.What do these results mean?This study shows that eliglustat is effective for a wide range of adults with Gaucher disease type 1. This real-world study differed from clinical trials by including patients who would not have met standard trial eligibility requirements.Clinical trials excluded people who: Had their spleen removed (splenectomy)Recently received other GD treatmentHad other significant health conditionsThis real-world study included: People who had a splenectomy at any timePeople who switched from other GD treatments to eliglustatA more diverse group of patients with varying health backgroundsThis study shows that eliglustat: Works well outside of research settingsHelped improve or maintain important health measures over many years of treatmentIs a reliable oral treatment option for many people living with GD1These findings support the continued use of eliglustat as a treatment choice in routine clinical practiceHow to say (download PDF and double click sound icon to play sound)…Beta-glucosidase: BAY-tuh-GLOO-koh-SIH-daysEliglustat: EL-i-GLOO-statEnzyme: EN-zimeGaucher Disease: Go-SHAY diz-EEzGlycosphingolipids: GLY-koh-SFIN-goh-LIH-pidsHaemoglobin: HEE-muh-GLOH-binSphingolipids: SFING-goh-LIH-pidsSplenectomy: Spleh-NEK-toh-meeThis is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-textLink to original article here
2026-08-04 | Industry Insights: Expanding access across the field, from pediatric approvals to the first solid tumor CAR‑T
July 2026 saw the field push access outward on multiple fronts, from the first FDA approval of a genetic therapy for children as young as 2 years (Vertex’s CASGEVY) to the first international patient treated with satri‑cel, the first CAR‑T therapy approved anywhere for a solid tumor. Regulatory momentum extended across in vivo CAR‑T, allogeneic transplant, and solid tumor cell therapy, while ARPA‑H committed up to $160 million to scalable in vivo gene editing for rare diseases. Alongside these milestones, new partnerships, a €33 million financing, and first patient dosings in pivotal trials for Gaucher disease type 1 and diabetic retinopathy signaled continued investment across the manufacturing, clinical, and commercial landscape.
2026-07-31 | 4-Dehydroxymethyl-4-C-biphenyl-DAB derivatives: introduction of a biphenyl group at the C4 position shifts the binding selectivity, resulting in improved affinity for lysosomal acid β-glucocerebrosidase.
Pharmacological chaperones can enhance the stability of the three-dimensional structure by reversibly binding to the active site of mutant enzymes, thereby promoting maturation within the cell and transport to the lysosome. This study provides an example of a high-affinity ligand design strategy for lysosomal acid β-glucocerebrosidase (GCase), focusing on introducing a biphenyl substituent at the C4 position of 1,4-dideoxy-1,4-imino-D-arabinitol (DAB) in place of the native hydroxymethyl group. The introduction of a p-CF3-biphenyl group at the C4 position shifted the binding selectivity of DAB from α-glucosidase to β-glucosidase while simultaneously increasing binding affinity by 4289-fold compared to DAB, exhibiting nanomolar affinity (Ki = 0.045 μM). These findings suggest a novel possibility that contradicts the conventional view that modification of the hydroxymethyl group at the C4 position of the pyrrolidine ring inevitably leads to loss of sugar recognition ability and a consequent decrease in binding affinity. The docking models and molecular dynamics simulations showed that para-trifluoromethyl substitution restricts the mobility of the B-ring of the biphenyl moiety within the hydrophobic pocket of GCase. This interaction of the para-trifluoromethyl group and the hydrophobic pocket stabilises the active site architecture and markedly suppresses dynamic fluctuations of loop 1 and loop 2 compared with fluctuations observed in the isofagomine complex, thereby contributing to enhanced thermodynamic stabilisation of the enzyme. 4-Dehydroxymethyl-4-C-(p-CF3-biphenyl)-DAB (6e) dose dependently increased intracellular GCase activity in V394L and L444P mutant cells. It is noteworthy that the effective dose was about 10-fold lower than that for isofagomine. Therefore, 4-dehydroxymethyl-4-C-(p-CF3-biphenyl)-DAB (6e) is expected to increase intracellular mutant enzyme activity and may represent a useful therapeutic option for the treatment of Gaucher disease.
2026-07-09 | Intra-CNS AAV9-GBA1 delivery yields species and route of administration differences in safety and transgene expression.
Adeno-associated virus (AAV) delivery of lysosomal enzymes to the brain is currently being tested in several clinical trials. However, publicly available non-human primate (NHP) studies comprehensively reporting biodistribution, transgene expression, and safety across the central nervous system (CNS) remain limited. Here, we examined AAV9-GBA1 (encoding glucocerebrosidase [GCase]) delivery to mice and NHPs. Loss-of-function GBA1 mutations cause Gaucher's disease and are risk factors for Parkinson's disease and dementia with Lewy bodies. In mice, early postnatal intracerebroventricular administration produced appreciable transgene expression and increased GCase activity in the brain without adverse findings. Two independent adult NHP studies evaluated AAV9-GBA1 brain delivery via intracisterna magna (ICM) and intraparenchymal (IPa) administration. ICM delivery produced considerable transgene expression in the spinal cord and dorsal root ganglia (DRG) neurons along with adverse microscopic findings, but limited brain expression and activity. In contrast, IPa delivery into the thalamus and/or putamen produced substantial transgene expression and GCase activity in injected and connected brain regions, with limited effects in distal regions, including the spinal cord. While no AAV-related DRG toxicity was detected with IPa, procedure- and AAV9-GBA1-related adverse microscopic brain findings were observed and associated with clinical outcomes. Further technological advances are needed to achieve safe and therapeutic AAV transgene expression in NHP brain.
2026-06-23 | Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies.
Neuronopathic Gaucher disease (nGD) is a lysosomal storage disorder caused by GBA1 mutations, leading to defective acid β-glucosidase (GCase) and accumulation of glycosphingolipid substrates, causing inflammation and neurodegeneration. Patients with nGD manifest severe neurological symptoms, but current animal models fail to fully recapitulate the human condition, posing a major barrier to the development of effective therapies targeting the brain. To bridge this gap, we have developed midbrain-like organoids (MLOs) from human induced pluripotent stem cells of nGD patients with GBA1L444P/P415R and GBA1L444P/RecNcil mutations to model nGD brain pathogenesis. These nGD MLOs exhibited GCase deficiency, resulting in diminished enzymatic function, accumulation of lipid substrates, widespread transcriptomic changes, and impaired dopaminergic neuron differentiation, mirroring nGD pathology. GBA1 mutation correction mediated by CRISPR/Cas9 restored GCase activity, normalized lipid substrate levels, and rescued dopaminergic neuron function, confirming the causal role of GBA1 mutations during early brain development. Using this novel platform, we further evaluated therapeutic strategies, including SapC-DOPS nanovesicles delivering GCase, AAV9-GBA1 gene therapy, and substrate reduction therapy with GZ452, a glucosylceramide synthase inhibitor currently under clinical investigation. These treatments either restored GCase activity, reduced lipid substrate accumulation, improved autophagic and lysosomal abnormalities, or ameliorated dysregulated genes involved in neural development. These patient-specific, 3D neural models offer a transformative, physiologically relevant platform for unraveling disease mechanisms and accelerating the discovery of therapies for patients with nGD.
2026-08-06 | Plain language summary: A real-world analysis of long-term treatment with eliglustat in people with Gaucher disease type 1
Plain Language SummaryWhat did this study look at?Gaucher disease type 1 (GD1) is a rare genetic condition. It results from a problem with an enzyme (a protein that speeds up chemical reactions in the body) called acid beta-glucosidase. This enzyme normally helps break down excess fats in the body called sphingolipids. As a result, fats build up inside certain cells (called lysosomes) especially in organs like the liver and spleen, in bones, and in the blood. Symptoms of GD1 include enlarged liver and spleen, low haemoglobin (a protein in red blood cells that carries oxygen), low platelets (specialised blood cells that help blood clot), poor bone health, and fatigue.People with GD1 experience a wide range of symptoms, severity, and disease worsening. This makes it difficult to understand how well treatments work in everyday clinical care as clinical trials often include only a limited group of patients.The study looks at how effective (how well something works) eliglustat is in routine clinical practice across a broader spectrum of adults with GD1 than those who participated in clinical trials.Researchers used data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. This is a global database that follows people with Gaucher disease over many years. Since the Registry includes people with diverse backgrounds, disease severities, and treatment histories, it provides valuable insight into how treatments perform outside of controlled trials.Using this real-world data, the study examines long-term outcomes in adults with GD1 who started eliglustat. This includes both people who had never received treatment before and those who switched from enzyme replacement therapy (ERT).What were the results of the study?Researchers looked at adults with GD1 who started eliglustat treatment and followed them for up to 10 years.For people who had not received any treatment for Gaucher disease (GD) prior to receiving eliglustat, blood counts and organ size (spleen and liver) improved and bone health (measured by bone mineral density) remained stable over 4 years. For people who switched to eliglustat after receiving ERT, blood counts, organ size (spleen and liver), and bone health remained stable after switching to eliglustat.What do these results mean?This study shows that eliglustat is effective for a wide range of adults with Gaucher disease type 1. This real-world study differed from clinical trials by including patients who would not have met standard trial eligibility requirements.Clinical trials excluded people who: Had their spleen removed (splenectomy)Recently received other GD treatmentHad other significant health conditionsThis real-world study included: People who had a splenectomy at any timePeople who switched from other GD treatments to eliglustatA more diverse group of patients with varying health backgroundsThis study shows that eliglustat: Works well outside of research settingsHelped improve or maintain important health measures over many years of treatmentIs a reliable oral treatment option for many people living with GD1These findings support the continued use of eliglustat as a treatment choice in routine clinical practiceHow to say (download PDF and double click sound icon to play sound)…Beta-glucosidase: BAY-tuh-GLOO-koh-SIH-daysEliglustat: EL-i-GLOO-statEnzyme: EN-zimeGaucher Disease: Go-SHAY diz-EEzGlycosphingolipids: GLY-koh-SFIN-goh-LIH-pidsHaemoglobin: HEE-muh-GLOH-binSphingolipids: SFING-goh-LIH-pidsSplenectomy: Spleh-NEK-toh-meeThis is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-textLink to original article here
2026-08-04 | Industry Insights: Expanding access across the field, from pediatric approvals to the first solid tumor CAR‑T
July 2026 saw the field push access outward on multiple fronts, from the first FDA approval of a genetic therapy for children as young as 2 years (Vertex’s CASGEVY) to the first international patient treated with satri‑cel, the first CAR‑T therapy approved anywhere for a solid tumor. Regulatory momentum extended across in vivo CAR‑T, allogeneic transplant, and solid tumor cell therapy, while ARPA‑H committed up to $160 million to scalable in vivo gene editing for rare diseases. Alongside these milestones, new partnerships, a €33 million financing, and first patient dosings in pivotal trials for Gaucher disease type 1 and diabetic retinopathy signaled continued investment across the manufacturing, clinical, and commercial landscape.
2026-07-31 | 4-Dehydroxymethyl-4-C-biphenyl-DAB derivatives: introduction of a biphenyl group at the C4 position shifts the binding selectivity, resulting in improved affinity for lysosomal acid β-glucocerebrosidase.
Pharmacological chaperones can enhance the stability of the three-dimensional structure by reversibly binding to the active site of mutant enzymes, thereby promoting maturation within the cell and transport to the lysosome. This study provides an example of a high-affinity ligand design strategy for lysosomal acid β-glucocerebrosidase (GCase), focusing on introducing a biphenyl substituent at the C4 position of 1,4-dideoxy-1,4-imino-D-arabinitol (DAB) in place of the native hydroxymethyl group. The introduction of a p-CF3-biphenyl group at the C4 position shifted the binding selectivity of DAB from α-glucosidase to β-glucosidase while simultaneously increasing binding affinity by 4289-fold compared to DAB, exhibiting nanomolar affinity (Ki = 0.045 μM). These findings suggest a novel possibility that contradicts the conventional view that modification of the hydroxymethyl group at the C4 position of the pyrrolidine ring inevitably leads to loss of sugar recognition ability and a consequent decrease in binding affinity. The docking models and molecular dynamics simulations showed that para-trifluoromethyl substitution restricts the mobility of the B-ring of the biphenyl moiety within the hydrophobic pocket of GCase. This interaction of the para-trifluoromethyl group and the hydrophobic pocket stabilises the active site architecture and markedly suppresses dynamic fluctuations of loop 1 and loop 2 compared with fluctuations observed in the isofagomine complex, thereby contributing to enhanced thermodynamic stabilisation of the enzyme. 4-Dehydroxymethyl-4-C-(p-CF3-biphenyl)-DAB (6e) dose dependently increased intracellular GCase activity in V394L and L444P mutant cells. It is noteworthy that the effective dose was about 10-fold lower than that for isofagomine. Therefore, 4-dehydroxymethyl-4-C-(p-CF3-biphenyl)-DAB (6e) is expected to increase intracellular mutant enzyme activity and may represent a useful therapeutic option for the treatment of Gaucher disease.
2026-07-09 | Intra-CNS AAV9-GBA1 delivery yields species and route of administration differences in safety and transgene expression.
Adeno-associated virus (AAV) delivery of lysosomal enzymes to the brain is currently being tested in several clinical trials. However, publicly available non-human primate (NHP) studies comprehensively reporting biodistribution, transgene expression, and safety across the central nervous system (CNS) remain limited. Here, we examined AAV9-GBA1 (encoding glucocerebrosidase [GCase]) delivery to mice and NHPs. Loss-of-function GBA1 mutations cause Gaucher's disease and are risk factors for Parkinson's disease and dementia with Lewy bodies. In mice, early postnatal intracerebroventricular administration produced appreciable transgene expression and increased GCase activity in the brain without adverse findings. Two independent adult NHP studies evaluated AAV9-GBA1 brain delivery via intracisterna magna (ICM) and intraparenchymal (IPa) administration. ICM delivery produced considerable transgene expression in the spinal cord and dorsal root ganglia (DRG) neurons along with adverse microscopic findings, but limited brain expression and activity. In contrast, IPa delivery into the thalamus and/or putamen produced substantial transgene expression and GCase activity in injected and connected brain regions, with limited effects in distal regions, including the spinal cord. While no AAV-related DRG toxicity was detected with IPa, procedure- and AAV9-GBA1-related adverse microscopic brain findings were observed and associated with clinical outcomes. Further technological advances are needed to achieve safe and therapeutic AAV transgene expression in NHP brain.
2026-06-23 | Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies.
Neuronopathic Gaucher disease (nGD) is a lysosomal storage disorder caused by GBA1 mutations, leading to defective acid β-glucosidase (GCase) and accumulation of glycosphingolipid substrates, causing inflammation and neurodegeneration. Patients with nGD manifest severe neurological symptoms, but current animal models fail to fully recapitulate the human condition, posing a major barrier to the development of effective therapies targeting the brain. To bridge this gap, we have developed midbrain-like organoids (MLOs) from human induced pluripotent stem cells of nGD patients with GBA1L444P/P415R and GBA1L444P/RecNcil mutations to model nGD brain pathogenesis. These nGD MLOs exhibited GCase deficiency, resulting in diminished enzymatic function, accumulation of lipid substrates, widespread transcriptomic changes, and impaired dopaminergic neuron differentiation, mirroring nGD pathology. GBA1 mutation correction mediated by CRISPR/Cas9 restored GCase activity, normalized lipid substrate levels, and rescued dopaminergic neuron function, confirming the causal role of GBA1 mutations during early brain development. Using this novel platform, we further evaluated therapeutic strategies, including SapC-DOPS nanovesicles delivering GCase, AAV9-GBA1 gene therapy, and substrate reduction therapy with GZ452, a glucosylceramide synthase inhibitor currently under clinical investigation. These treatments either restored GCase activity, reduced lipid substrate accumulation, improved autophagic and lysosomal abnormalities, or ameliorated dysregulated genes involved in neural development. These patient-specific, 3D neural models offer a transformative, physiologically relevant platform for unraveling disease mechanisms and accelerating the discovery of therapies for patients with nGD.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
3 orphan drug designations for Gaucher disease type 1, including 2 approved therapies.
3 orphan drug designations for Gaucher disease type 1, including 2 approved therapies.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Eliglustat Tartrate | small molecules | FDA | 2021-09-02 | — | Amneal Pharmaceuticals LLC |
eliglustat [CERDELGA] | small molecules | FDA | 2008-09-17 | 2014-08-19 | Genzyme Corporation |
Alglucerase injection [Ceredase] | proteins | FDA | 1985-03-11 | 1991-04-05 | Genzyme Corporation |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.